Physiologic Growth Hormone Effects in HIV Lipodystrophy
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
This study will investigate long-term, low-dose growth hormone administration in HIV-infected
patients with reduced growth hormone (GH) secretion and increased visceral adiposity. We
hypothesize that low-dose growth hormone will reduce visceral fat. Secondary endpoints will
include measures of insulin-like growth factor-1 (IGF-1), glucose homeostasis, lipids, blood
pressure,bone density, cardiovascular risk and safety parameters.
Phase:
N/A
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)